Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

IL6 Supports Development of an Immunosuppressive Microenvironment and Resistance to Therapy in Glioblastoma.

Cancer research·2026
Same author

Tele-cognitive rehabilitation for adult lower-grade glioma: An interim prospective pilot feasibility study.

Neuro-oncology practice·2026
Same author

A Genomically Tailored Multiagent Precision Medicine Clinical Trial for Adults with Recurrent Glioblastoma.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Longitudinal profiling of IDH-mutant astrocytomas reveals acquired RAS-MAPK pathway mutations associated with inferior survival.

Neuro-oncology advances·2025
Same author

Correction: Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways.

Cancer discovery·2025
Same author

Longitudinal multimodal profiling of IDH-wildtype glioblastoma reveals the molecular evolution and cellular phenotypes underlying prognostically different treatment responses.

Neuro-oncology·2024

Related Experiment Video

Updated: Mar 9, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.9K

Treatment options for recurrent high-grade gliomas.

Harjus S Birk1, Seunggu J Han1, Nicholas A Butowski1

  • 1Department of Neurological Surgery, University of California, San Francisco, CA, USA.

CNS Oncology
|December 22, 2016
PubMed
Summary

Recurrent glioblastoma (GB) treatment is challenging due to tumor heterogeneity. This review analyzes re-resection, chemotherapy, and immunotherapy strategies to improve overall survival for aggressive brain tumors.

Keywords:
glioblastomahigh-grade gliomasoverall survivalprogression-free survivalrecurrence treatment

More Related Videos

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma
08:00

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

19.5K
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

22.1K

Related Experiment Videos

Last Updated: Mar 9, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.9K
The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma
08:00

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

19.5K
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

22.1K

Area of Science:

  • Neuro-oncology
  • Cancer Biology
  • Clinical Therapeutics

Background:

  • High-grade gliomas, including glioblastoma (GB), are aggressive brain tumors.
  • GB exhibits high recurrence rates post-initial resection, necessitating effective recurrent treatment strategies.
  • Current therapeutic options for recurrent GB are less established than for newly diagnosed cases.

Purpose of the Study:

  • To review and analyze current therapeutic strategies for recurrent high-grade gliomas.
  • To assess the impact of various treatments on overall survival in recurrent GB.
  • To highlight the need for novel therapies targeting GB recurrence due to tumor heterogeneity.

Main Methods:

  • Literature review of studies on recurrent glioblastoma management.
  • Analysis of therapeutic approaches including re-resection, bevacizumab, chemotherapy, targeted molecular therapies, immunotherapy, and radiotherapy.
  • Evaluation of treatment efficacy based on overall survival data.

Main Results:

  • Evidence supports re-resection, bevacizumab, chemotherapy, targeted therapies, immunotherapy, and radiotherapy in recurrent GB.
  • These therapies show varying effects on overall survival, requiring further investigation.
  • Tumor heterogeneity in GB presents a significant challenge for treatment efficacy.

Conclusions:

  • Effective management of recurrent GB requires a multifaceted therapeutic approach.
  • Ongoing research into novel therapeutic targets and strategies is crucial for improving outcomes in high-grade gliomas.
  • Understanding and overcoming GB tumor heterogeneity is key to developing more successful treatments.